2.2 Negative Regulation of Ferroptosis by p53 In addition to its ferroptosis-promoting effects, p53 represses ferroptosis by inducing cyclin-dependent kinase inhibitor (CDKN1A, encoding p21), Parkinson disease 2 (PARK2) and iPLA2, or by inhibiting dipeptidyl peptidase-4 (DPP4) (Kang et al., 2019) (Figure 2)
Warnings Consult your doctor before use if you are pregnant, breastfeeding, or have any medical conditions
Adherence, Persistence, and Patient Experience Even when patients overcome access barriers and initiate treatment, the next challenge is staying on therapy long enough to achieve meaningful and sustained outcomes
In the SURMOUNT-1 trial, also published in NEJM, participants receiving tirzepatide achieved weight reductions ranging from 16.0% to 22.5% depending on dose over 72 weeks
In fact, 96% of sensitive skins agree that C-Tetra is gentle on the skin